Pirow Bekker

8.1k total citations · 4 hit papers
76 papers, 5.8k citations indexed

About

Pirow Bekker is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Pirow Bekker has authored 76 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 18 papers in Immunology. Recurrent topics in Pirow Bekker's work include Bone health and treatments (22 papers), Vasculitis and related conditions (20 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (13 papers). Pirow Bekker is often cited by papers focused on Bone health and treatments (22 papers), Vasculitis and related conditions (20 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (13 papers). Pirow Bekker collaborates with scholars based in United States, United Kingdom and Sweden. Pirow Bekker's co-authors include Donna Holloway, Thomas J. Schall, David Jayne, Colin R. Dunstan, Philip T. Leese, Peter A. Merkel, Stanley Cohen, Mark Peterson, Steven W. Martin and Paul D. Miller and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Pirow Bekker

75 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Denosumab in Postmenopausal Women with Low Bone Mineral Density

2006 886 citations Michael R. McClung, E. Michael Lewiecki et al. New England Journal of Medicine profile →
A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women

2004 591 citations Pirow Bekker, Donna Holloway et al. profile →
Avacopan for the Treatment of ANCA-Associated Vasculitis

2021 548 citations David Jayne, Thomas J. Schall et al. New England Journal of Medicine profile →
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis

2017 420 citations David Jayne, Annette Bruchfeld et al. Journal of the American Society of Nephrology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pirow Bekker United States	27	3.0k	2.1k	1.6k	1.2k	1.2k	76	5.8k
Roger Dansey United States	30	5.2k 1.7×	1.4k 0.7×	1.8k 1.1×	453 0.4×	2.1k 1.7×	122	7.6k
Maria Greenwald United States	30	1.2k 0.4×	607 0.3×	845 0.5×	1.5k 1.2×	141 0.1×	76	5.1k
Ingo Diel Germany	36	5.1k 1.7×	1.0k 0.5×	1.5k 0.9×	522 0.4×	1.2k 1.0×	113	6.5k
Catherine Van Poznak United States	39	5.2k 1.7×	1.3k 0.6×	1.7k 1.1×	152 0.1×	1.7k 1.4×	150	7.3k
Ashraf Badros United States	46	3.5k 1.2×	3.3k 1.6×	597 0.4×	689 0.6×	301 0.2×	173	7.1k
Aristotelis Bamias Greece	36	3.1k 1.0×	1.7k 0.8×	226 0.1×	569 0.5×	2.2k 1.8×	276	6.9k
Shunji Takahashi Japan	44	5.3k 1.8×	1.3k 0.6×	847 0.5×	391 0.3×	2.4k 2.0×	353	7.8k
Guenther G. Steger Austria	34	4.6k 1.5×	1.3k 0.6×	608 0.4×	350 0.3×	1.5k 1.2×	156	6.0k
Philippe Beuzeboc France	47	3.9k 1.3×	1.2k 0.5×	185 0.1×	215 0.2×	3.2k 2.7×	243	7.6k
Jean‐Paul Fermand France	34	1.4k 0.5×	2.3k 1.1×	95 0.1×	792 0.6×	303 0.2×	105	4.4k

Countries citing papers authored by Pirow Bekker

Since Specialization

Citations

This map shows the geographic impact of Pirow Bekker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pirow Bekker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pirow Bekker more than expected).

Fields of papers citing papers by Pirow Bekker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pirow Bekker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pirow Bekker. The network helps show where Pirow Bekker may publish in the future.

Co-authorship network of co-authors of Pirow Bekker

This figure shows the co-authorship network connecting the top 25 collaborators of Pirow Bekker. A scholar is included among the top collaborators of Pirow Bekker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pirow Bekker. Pirow Bekker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Miao, Shichang, et al.. (2024). Food Effect and Pharmacokinetic Bridging of Avacopan in Caucasian and Japanese Healthy Participants. Clinical Pharmacology in Drug Development. 13(9). 1011–1023. 2 indexed citations

Patel, Naomi J., David Jayne, Peter A. Merkel, et al.. (2023). Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial. The Lancet Rheumatology. 5(3). e130–e138. 10 indexed citations

Cortazar, Frank B., David Jayne, Annette Bruchfeld, & Pirow Bekker. (2022). Renal Recovery for Patients With Baseline eGFR ≤20 in Avacopan ADVOCATE Trial. Journal of the American Society of Nephrology. 33(11S). 501–501. 1 indexed citations

Bomback, Andrew S., et al.. (2021). Effect of Avacopan, a Selective C5a Receptor Inhibitor, on C3G Histologic Index of Disease Chronicity. Journal of the American Society of Nephrology. 32(10S). B9–B10. 2 indexed citations

Merkel, Peter A., et al.. (2020). Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial. JMIR Research Protocols. 9(4). e16664–e16664. 46 indexed citations

Jayne, David, Annette Bruchfeld, Lorraine Harper, et al.. (2017). Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. Journal of the American Society of Nephrology. 28(9). 2756–2767. 420 indexed citations breakdown →

Bekker, Pirow, Daniel J. Dairaghi, Lisa Seitz, et al.. (2016). Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS ONE. 11(10). e0164646–e0164646. 115 indexed citations

Bekker, Pirow, Karen Ebsworth, Matthew J. Walters, et al.. (2015). CCR9 Antagonists in the Treatment of Ulcerative Colitis. Mediators of Inflammation. 2015(1). 628340–628340. 18 indexed citations

Zeeuw, Dick de, Pirow Bekker, Elena Henkel, et al.. (2015). The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. The Lancet Diabetes & Endocrinology. 3(9). 687–696. 220 indexed citations

10.

Jayne, David, Annette Bruchfeld, Matthias Schaier, et al.. (2014). Phase 2 randomised trial of oral C5A receptor antagonist CCX168 in ANCA-associated renal vasculitis. Nephrology Dialysis Transplantation. 29. 4 indexed citations

11.

Keshav, Satish, Tomáš Vaňásek, Yaron Niv, et al.. (2013). A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease. PLoS ONE. 8(3). e60094–e60094. 110 indexed citations

12.

Tak, Paul P., Andra Bălănescu, Vira Tseluyko, et al.. (2012). Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Annals of the Rheumatic Diseases. 72(3). 337–344. 76 indexed citations

13.

Walters, Matthew J., Yu Wang, Trageen Baumgart, et al.. (2010). Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease. Journal of Pharmacology and Experimental Therapeutics. 335(1). 61–69. 130 indexed citations

14.

Wei, Zhicheng, Werner Rubas, Trageen Baumgart, et al.. (2008). MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B. Oxford University Research Archive (ORA) (University of Oxford). 235. 1 indexed citations

15.

Keshav, Satish, Robert Petryka, Yaron Niv, et al.. (2007). PROTECT-1: A Prospective Randomized Trial of CCX282-B (Traficet-EN), a Novel Oral Therapy Targeting Chemokine Receptor 9 in Crohnʼs Disease. The American Journal of Gastroenterology. 102. S475–S475. 1 indexed citations

16.

McClung, Michael R., E. Michael Lewiecki, Stanley Cohen, et al.. (2006). Denosumab in Postmenopausal Women With Low Bone Mineral Density. Obstetrical & Gynecological Survey. 61(6). 384–386. 16 indexed citations

17.

McClung, Michael R., E. Michael Lewiecki, Stanley Cohen, et al.. (2006). Denosumab in Postmenopausal Women with Low Bone Mineral Density. New England Journal of Medicine. 354(8). 821–831. 886 indexed citations breakdown →

18.

Genovese, Mark C., Stanley Cohen, Larry W. Moreland, et al.. (2004). Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis & Rheumatism. 50(5). 1412–1419. 385 indexed citations

19.

Brown, Jacques P., Jelle W. Kylstra, Pirow Bekker, et al.. (1994). Risedronate in Paget's disease: Preliminary results of a multicenter study. Seminars in Arthritis and Rheumatism. 23(4). 272–272. 13 indexed citations

20.

Gay, Carol V., et al.. (1993). Effect of Estrogen on Acidification in Osteoclasts. Biochemical and Biophysical Research Communications. 192(3). 1251–1259. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact